With a population of 1.3 billion people and a rapidly expanding economy, China has recently risen to become the third largest pharmaceutical market globally. Several multinational pharmaceutical companies have now located R&D centres in China, and Chinese pharmaceutical companies are increasingly focusing on innovative drug R&D.
- R&D Trends of Innovative Drugs
- R&D Environment of Innovative Drugs in China
- Rapid Evaluation and Marketing of Innovative Drugs
- "Bring in" and "Going out" Strategies of Innovative Drugs
- Incorporation of Innovative Drugs into the Catalogue of Medical Insurance Reimbursement
- Innovation of Vigor: Promotion of Drug R&D by AI
- New Indications of Existing Drugs
- Innovative Drugs and Pharmaceutical Technologies
- Innovation and Translation of Scientific Research in Universities
- Pilot Policy of Marketing Authorization Holder
- Individualized Medicine: Small Molecule Targeted Drugs, Monoclonal Antibodies, Innovative Cancer Drugs, "Living Cell" Drugs
- From RCT to RWS: Post-Marketing Real World Study
- Overseas BD Opportunities for New Drug Projects
- Opportunities and Challenges for China After Joining the ICH
The latest trends of innovative drug R&D will be analyzed.
The latest technologies of innovative drug R&D will be displayed
Excellent projects of innovative drug R&D will be shown and evaluated.
Researchers from Universities and Institutes
Personnels from Pharmaceutical Companies
Clinicians
Dear Mr./Ms.
You have registered successfully, the registration information and attention has been sent to the contact and the participants of the mailbox, please note that check. If not received, please contact the general meeting
